Eventide Asset Management’s Kite Pharma, Inc. KITE Stock Holding History

Eventide Asset Management’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-85,000	Closed	-$8.81M	–	139
2017 Q2	$8.81M	Sell	85,000 -43,000	-34%	-$3.51M	0.55%	53
2017 Q1	$10M	Hold	128,000	–	–	0.67%	51
2016 Q4	$5.74M	Sell	128,000 -20,600	-14%	-$1.01M	0.37%	68
2016 Q3	$8.3M	Hold	148,600	–	–	0.51%	56
2016 Q2	$7.43M	Hold	148,600	–	–	0.45%	61
2016 Q1	$6.82M	Hold	148,600	–	–	0.38%	65
2015 Q4	$9.16M	Buy	148,600 +8,600	+6%	+$605K	0.46%	59
2015 Q3	$7.79M	Buy	+140,000	New	+$8.81M	0.45%	59

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Eventide Asset Management's KITE Position: Q3 2017 in Review

Eventide Asset Management sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 85,000 shares — an estimated $8.81M sold.

Eventide Asset Management first reported a position in KITE in Q3 2015 and held it in 8 quarters. The position peaked at $10M in Q1 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Eventide Asset Management reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Eventide Asset Management sold 85,000 Kite Pharma, Inc. shares in Q3 2017, an estimated $8.81M.
Eventide Asset Management first reported a position in Kite Pharma, Inc. in Q3 2015 and held it in 8 quarters.
Eventide Asset Management's Kite Pharma, Inc. position peaked at $10M in Q1 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Eventide Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.